Patents by Inventor Jerome Etienne

Jerome Etienne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the in vitro detection of strains of resistant to antibiotics
    Patent number: 10106858
    Abstract: Disclosed is a method for the in vitro detection of strains of Legionella pneumophila, resistant to antibiotics, in particular to the fluoroquinolones. Also disclosed are nucleotide probes and a kit of reagents allowing the detection of Legionella pneumophila bacterial strains that are resistant to antibiotics, in particular of the fluoroquinolone type.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: October 23, 2018
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES
    Inventors: Max Maurice Louis Maurin, Dominique Schneider, Lubana Shadoud, Sophie Jarraud, Jean Francois Timsit, Jerome Etienne
  • METHOD FOR THE IN VITRO DETECTION OF STRAINS OF LEGIONELLA PNEUMOPHILA RESISTANT TO ANTIBIOTICS
    Publication number: 20160208316
    Abstract: Disclosed is a method for the in vitro detection of strains of Legionella pneumophila, resistant to antibiotics, in particular to the fluoroquinolones. Also disclosed are nucleotide probes and a kit of reagents allowing the detection of Legionella pneumophila bacterial strains that are resistant to antibiotics, in particular of the fluoroquinolone type.
    Type: Application
    Filed: June 17, 2014
    Publication date: July 21, 2016
    Inventors: Max Maurin Louis MAURIN, Dominique SCHNEIDER, Lubana SHADOUD, Sophie JARRAUD, Jean Francois TIMSIT, Jerome ETIENNE
  • Method for in vitro diagnosis of PVL-producing
    Patent number: 8936791
    Abstract: A method for in vitro diagnosis of Staphylococcus aureus producing Panton-Valentine Leukocidin (PVL), using a biological sample derived from an individual liable to be colonized by or infected with Staphylococcus aureus, wherein the diagnosis is carried out by detection of PVL using a routine immunological test, and the biological sample is pretreated in order to denature the PVL.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: January 20, 2015
    Assignees: Biomerieux, Intstitut National de la Sante et de la Recherche Medicale (Inserm), Universite Claude Bernard Lyon 1 (UCBL)
    Inventors: Cedric Badiou, Jerome Etienne, Gerard Lina, Catherine Ratat
  • Method for in vitro diagnosis of pvl-producing staphylococcus aureus
    Publication number: 20100129839
    Abstract: The present invention relates to a method for in vitro diagnosis of Staphylococcus aureus producing Panton-Valentine Leukocidin (PVL), using a biological sample derived from an individual liable to be colonized by or infected with Staphylococcus aureus, wherein the diagnosis is carried out by detection of PVL using a routine immunological test, characterized in that said biological sample is pretreated in order to denature the PVL.
    Type: Application
    Filed: October 16, 2007
    Publication date: May 27, 2010
    Applicants: BIOMERIEUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL)
    Inventors: Cedric Badiou, Jerome Etienne, Gerard Lina, Catherine Ratat
  • Enterotoxin gene cluster (egc) superantigens to treat malignant disease
    Publication number: 20090162315
    Abstract: The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size.
    Type: Application
    Filed: June 27, 2005
    Publication date: June 25, 2009
    Inventors: David S. Terman, Jerome Etienne, Francois Vaudensch, Gerard Lina, Gregory A. Bohach